ATE538108T1 - Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten - Google Patents

Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten

Info

Publication number
ATE538108T1
ATE538108T1 AT06022992T AT06022992T ATE538108T1 AT E538108 T1 ATE538108 T1 AT E538108T1 AT 06022992 T AT06022992 T AT 06022992T AT 06022992 T AT06022992 T AT 06022992T AT E538108 T1 ATE538108 T1 AT E538108T1
Authority
AT
Austria
Prior art keywords
treatment
neurodegenerative diseases
compounds
hydrazides
thiazole
Prior art date
Application number
AT06022992T
Other languages
English (en)
Inventor
Eckhard Mandelkow
Eva-Maria Mandelkow
Markus Pickhardt
Jacek Biernat
David George Lioyd
Prof Boris Schmidt
Dr Gregor Larbig
Original Assignee
Max Planck Gesellschaft
Univ Darmstadt Tech
Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Holy & Undi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Univ Darmstadt Tech, Provost Fellows Foundation Scholars And The Other Members Of Board Of The College Of The Holy & Undi filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE538108T1 publication Critical patent/ATE538108T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06022992T 2006-11-05 2006-11-05 Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten ATE538108T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06022992A EP1918286B1 (de) 2006-11-05 2006-11-05 Thiazolhydrazide und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten

Publications (1)

Publication Number Publication Date
ATE538108T1 true ATE538108T1 (de) 2012-01-15

Family

ID=37891535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06022992T ATE538108T1 (de) 2006-11-05 2006-11-05 Thiazolhydrazide und deren verwendung zur behandlung von neurodegenerativen krankheiten

Country Status (4)

Country Link
US (1) US8410152B2 (de)
EP (1) EP1918286B1 (de)
AT (1) ATE538108T1 (de)
WO (1) WO2008052804A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160024071A1 (en) * 2013-03-15 2016-01-28 Elan Pharmaceuticals, Llc Inhibitors of lrrk2 kinase activity
CN105287410A (zh) * 2015-12-01 2016-02-03 青岛华之草医药科技有限公司 治疗外伤性昏迷的药物盐酸甲氯芬酯组合物冻干粉针剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914322A1 (de) * 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. Neue indolyl und benzofuranylcarboxamide als inhibitoren der stickoxidproduktion
US20040132788A1 (en) * 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
ATE294794T1 (de) * 2001-10-04 2005-05-15 Ortho Mcneil Pharm Inc N-heterocyclylhydrazide als neurotrophe mittel
AU2003265068A1 (en) * 2002-10-09 2004-05-04 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
WO2004046154A1 (en) * 2002-11-15 2004-06-03 Orchid Chemicals & Pharmaceuticals Ltd Novel amorphous hydrate of a cephalosporin antibiotic
US7563812B2 (en) * 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate

Also Published As

Publication number Publication date
WO2008052804A1 (en) 2008-05-08
US8410152B2 (en) 2013-04-02
EP1918286B1 (de) 2011-12-21
US20100151064A1 (en) 2010-06-17
EP1918286A1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
ATE530519T1 (de) Cyclobutylaminderivate
NZ596579A (en) Bace inhibitors
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
EA200801997A1 (ru) Новые соединения
EA201000098A1 (ru) Производные хиназолинамида
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
EA200971106A1 (ru) Соединения с семичленным кольцом и их фармацевтические применения для предупреждения и лечения диабета и метаболического синдрома
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
EP2602255A4 (de) Fusionierte heterozyklische ringverbindung
TW200626158A (en) Naphthaline derivatives
ATE538119T1 (de) Benzothiazolcyclobutylamin-derivate und deren verwendung als histamin-3-rezeptor-liganden
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.